|
|
 |
 |
|
|
Celtic Pharma is currently conducting 1 clinical trial for XERECEPT. The following information will help to determine if you qualify for one of these clinical trials. If you have questions regarding this information, please see the list of study locations on this website and contact the clinic most convenient to you.
NTI 0302 – for patients needing dexamethasone (Decadron®)* to manage acute and worsening symptoms (0302 study is now closed to enrolment)
This study is for patients with brain tumors and tumor-associated swelling who require Decadron to control acute and worsening symptoms of brain swelling (edema).
This study will try to determine if treatment with XERECEPT is as effective and safe as treatment with Decadron for patients with brain tumors and tumor-associated swelling.
After the final follow-up visit, patients who participate in this study may choose to participate in an extended-use study (NTI 0501 - see below) in which XERECEPT will be made available to trial participants free of charge.
Click here for a description of the study inclusion and exclusion criteria for NTI 0302. |
|
|
|
|
|
|
NTI 0303 – for patients taking dexamethasone (Decadron) on a long-term basis (0303 study is now closed to enrolment)
This study is for patients with brain tumors and tumor-associated swelling who are taking chronic high doses of Decadron to control their neurological symptoms.
This study will try to determine if treatment with XERECEPT is as effective and safe as treatment with Decadron in patients with brain tumors and tumor-associated swelling. This study is also trying to find out if patients taking XERECEPT will be able to reduce their dose of Decadron without neurological symptoms returning.
After the final follow-up visit, patients who participate in this study may participate in an extended-use study in which XERECEPT will be made available to trial participants free of charge.
Click here for a description of the study inclusion and exclusion criteria for NTI 0303. |
|
|
|
|
|
|
NTI 0501 – open-label study for patients who have already participated in NTI 0302 or NTI 0303
After participating in one of the two studies mentioned above, you may be eligible to participate in this extended use study of XERECEPT for patients with brain tumors and tumor-associated swelling.
The purpose of this study is to determine if treatment with XERECEPT is safe for patients who require treatment with Decadron to control the symptoms of brain swelling (edema).
Click here for a description of the study inclusion and exclusion criteria for NTI 0501.
*Decadron is a registered trademark of Merck & Co., Inc. |
|
|
|
|
